TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing the Re-Engineered Hospital Discharge
Brief Summary: The purpose of this study is to determine if the "Re-Engineered Discharge" will decrease rehospitalization rates and adverse events of patients leaving Boston Medical Center.


Options:
A: Arm Label: Coordinated discharge; Type: EXPERIMENTAL; Interventions: Other: Coordinated discharge | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Coordinated discharge; Assigned to Arm(s): Coordinated discharge | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Re-engineered hospital discharge; Type: EXPERIMENTAL; Interventions: Behavioral: Re-Engineered Hospital Discharge | Arm Label: Standard hospital discharge; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Re-Engineered Hospital Discharge; Assigned to Arm(s): Re-engineered hospital discharge
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: reconciliation | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: reconciliation; Assigned to Arm(s): intervention
D: Arm Label: Discharge planning services; Type: ACTIVE_COMPARATOR; Interventions: Other: PACT-HF Model | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PACT-HF Model; Assigned to Arm(s): Discharge planning services

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Testing the Re-Engineered Hospital Discharge
Brief Summary: The purpose of this study is to determine if the "Re-Engineered Discharge" will decrease rehospitalization rates and adverse events of patients leaving Boston Medical Center.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: C-TraIn; Type: EXPERIMENTAL; Interventions: Other: Care Transitions Innovation (C-TraIn) | Intervention Type: OTHER; Name: Care Transitions Innovation (C-TraIn); Assigned to Arm(s): C-TraIn
B: Arm Label: Re-engineered hospital discharge; Type: EXPERIMENTAL; Interventions: Behavioral: Re-Engineered Hospital Discharge | Arm Label: Standard hospital discharge; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Re-Engineered Hospital Discharge; Assigned to Arm(s): Re-engineered hospital discharge
C: Arm Label: MI + IVR; Type: EXPERIMENTAL; Interventions: Behavioral: MI + IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MI + IVR; Assigned to Arm(s): MI + IVR
D: Arm Label: Minimal intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Minimal intervention | Arm Label: Enhanced intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Minimal intervention; Assigned to Arm(s): Minimal intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Intervention; Assigned to Arm(s): Enhanced intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2B Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
Brief Summary: The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator (tPA).


Options:
A: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: tenecteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tissue plasminogen activator, tPA | Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tissue plasminogen activator, tPA; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
D: Arm Label: IA thrombolysis; Type: EXPERIMENTAL; Interventions: Other: Alteplase IA and/or mechanical thrombolysis | Arm Label: IV rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alteplase IV | Intervention Type: OTHER; Name: Alteplase IA and/or mechanical thrombolysis; Assigned to Arm(s): IA thrombolysis | Intervention Type: DRUG; Name: Alteplase IV; Assigned to Arm(s): IV rtPA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Zinc as Adjuvant Therapy in the Treatment of Severe Pneumonia in Nepalese Children at the Kanti Children's Hospital
Brief Summary: The aim of this study is to assess whether zinc given as adjuvant therapy to standard antibiotic treatment in children hospitalized for severe pneumonia reduces the duration of the severe illness and risk of treatment failure. A randomized double blind placebo controlled clinical trial will be conducted at the Kanti Hospital.


Options:
A: Intervention Type: DRUG; Name: ZINC; Assigned to Arm(s): N/A
B: Arm Label: Zinc group; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Zinc group | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo group
C: Arm Label: Zinc; Type: EXPERIMENTAL; Interventions: Drug: Zinc (zinc sulphate) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc (zinc sulphate); Assigned to Arm(s): Zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Danish Osteoporosis Prevention Study
Brief Summary: Hypothesis: Use of hormone replacement therapy (HRT) decreases the incidence of fractures in early postmenopausal women.

The project was initiated in 1990, and the inclusion ended in 1993. A total of 2,016 early postmenopausal women were divided into two groups: The first group accepted randomisation to HRT or not, and the second group was allowed to choose HRT or not.

The study was not blinded. Main measurements were fracture risk over 20 years, changes in bone mineral density over 20 years, and side effects, mainly breast cancer.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Micronized 17B-estradiol; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Hormone replacement therapy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Danish Osteoporosis Prevention Study
Brief Summary: Hypothesis: Use of hormone replacement therapy (HRT) decreases the incidence of fractures in early postmenopausal women.

The project was initiated in 1990, and the inclusion ended in 1993. A total of 2,016 early postmenopausal women were divided into two groups: The first group accepted randomisation to HRT or not, and the second group was allowed to choose HRT or not.

The study was not blinded. Main measurements were fracture risk over 20 years, changes in bone mineral density over 20 years, and side effects, mainly breast cancer.


Options:
A: Intervention Type: DRUG; Name: Hormone replacement therapy; Assigned to Arm(s): N/A
B: Arm Label: Previous HT use and cognition; Type: N/A; Interventions: N/A
C: Intervention Type: DRUG; Name: Micronized 17B-estradiol; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Galantamine Versus Placebo in Childhood Autism
Brief Summary: Autism is a severe neurodevelopmental disorder that affects up to 16 in 10,000 individuals. It is a pervasive developmental disorder affecting social, communicative, and compulsive/repetitive behaviors characterized by stereotypic complex hand and body movements, craving for sameness, and narrow repetitive interests. Autism severely impacts both the affected individual and family members.

The proposed study is designed to assess the efficacy of treatment with Galantamine vs. placebo in childhood/adolescent autism fulfilling DSM-IV and Autism Diagnostic Interview (ADI) criteria. We therefore hypothesize:

1. Galantamine will be superior to placebo in the acute treatment of global autism.
2. Galantamine will be superior to placebo in improving functional ability.
3. Galantamine will be superior to placebo in improving language function.
4. Galantamine will be superior to placebo improving irritable and hyperactive behavior.
5. Galantamine will be superior to placebo in improving social deficits.


Options:
A: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Galantamine; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Divalproex Sodium; Type: EXPERIMENTAL; Interventions: Drug: Divalproex sodium | Intervention Type: DRUG; Name: Divalproex sodium; Assigned to Arm(s): Divalproex Sodium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Study of Early vs. Delayed Goal Enteral Nutrition in Mechanically Ventilated Patients
Brief Summary: This study tests the hypothesis that initial trophic enteral feedings will increase the time alive and free of mechanical ventilation as compared to initial goal enteral feedings in patients who are mechanically ventilated.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: trophic enteral feeds | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: trophic enteral feeds | Intervention Type: BEHAVIORAL; Name: trophic enteral feeds; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Full Feeding, Dietary Supplement: Placebo | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids and Antioxidant Supplements; Assigned to Arm(s): 1, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3, 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 1 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
D: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 1 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: candesartan cilexetil | Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
C: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
D: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 1 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Intervention Type: DRUG; Name: enalapril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): N/A
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control
D: Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.
Brief Summary: The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normoalbuminuric type 2 diabetic patients with retinopathy.

The secondary objective is to determine whether candesartan, compared to placebo, reduces the incidence of clinically significant macular oedema (CSME) and/or proliferative diabetic retinopathy (PDR) and beneficially influences the rate change in urinary albumin excretion rate (UAER).

This study is part of the DIRECT Programme also including a primary prevention study of diabetic retinopathy in type 1 diabetes and a secondary prevention study in type 1 diabetes. The primary objective for all three pooled studies is to determine whether candesartan, compared to placebo, reduces the incidence of microalbuminuria in type 1 and type 2 diabetic patients.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium channel blockers (amlodipine, azelnidipine) | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium channel blockers (amlodipine, azelnidipine); Assigned to Arm(s): 2
B: Arm Label: candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): candesartan
C: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
D: Arm Label: Intensive Treatment; Type: OTHER; Interventions: Drug: multi-factorial intervention | Intervention Type: DRUG; Name: multi-factorial intervention; Assigned to Arm(s): Intensive Treatment

Answer: B